Pexastimogene devacirepvec is under clinical development by Sillajen Biotherapeutics and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Pexastimogene devacirepvec’s likelihood of approval (LoA) and phase transition for Metastatic Renal Cell Carcinoma took place on 07 Jul 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Pexastimogene devacirepvec Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Pexastimogene devacirepvec overview

Pexastimogene devacirepvec (JX-594) is under development for the treatment of metastatic melanoma, muscle-invasive bladder cancer (MIBC), soft tissue sarcoma, breast cancer, solid tumor, stomach cancer, cholangiocarcinoma, prostate cancere, pancreatic cancer, renal cell carcinoma and metastatic colorectal cancer. The drug candidate is administered through intratumoral and intravenous routes. JX-594 is a Wyeth strain vaccinia virus with a disruption of the viral thymidine kinase (tk) gene and expression of the immunostimulatory cytokine, GM-CSF (granulocyte macrophage colony-stimulating factor). The drug candidate is developed based on SOLVE (Selective Oncolytic Vaccinia Engineering) platform.

It was also under development for the treatment of hepatocellular carcinoma, non-small cell lung cancer, head and neck cancer squamous cell carcinoma, colorectal cancer, kidney cancer and ovarian cancer.

Sillajen Biotherapeutics overview

Sillajen Biotherapeutics (SillaJen) is a biotechnology company. It designs and develops oncolytic immunotherapeutics for the treatment of cancer. The company’s pipeline products comprise Pexa-Vec, an oncolytic immunotherapeutic virus which is in Phase III trial that is used for the treatment of primary liver cancer. It also develops JX929, a chemosensitizing oncolytic immunotherapy that eradicates cancer; activates chemotherapy in cancer tissue; administers as a monotherapy to patients with breast, colorectal, and pancreatic cancer; and treats melanoma and metastatic colon cancer. The company operates in South Korea and the US. Sillajen is headquartered in San Francisco, the US.

Quick View Pexastimogene devacirepvec LOA Data

Report Segments
  • Innovator
Drug Name
  • Pexastimogene devacirepvec
Administration Pathway
  • Intratumor
  • Intravenous
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.